Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
16 Apr 2024
Historique:
received: 20 06 2023
accepted: 08 03 2024
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 16 4 2024
Statut: epublish

Résumé

Immune checkpoint inhibition has shown success in treating metastatic cutaneous melanoma but has limited efficacy against metastatic uveal melanoma, a rare variant arising from the immune privileged eye. To better understand this resistance, we comprehensively profile 100 human uveal melanoma metastases using clinicogenomics, transcriptomics, and tumor infiltrating lymphocyte potency assessment. We find that over half of these metastases harbor tumor infiltrating lymphocytes with potent autologous tumor specificity, despite low mutational burden and resistance to prior immunotherapies. However, we observe strikingly low intratumoral T cell receptor clonality within the tumor microenvironment even after prior immunotherapies. To harness these quiescent tumor infiltrating lymphocytes, we develop a transcriptomic biomarker to enable in vivo identification and ex vivo liberation to counter their growth suppression. Finally, we demonstrate that adoptive transfer of these transcriptomically selected tumor infiltrating lymphocytes can promote tumor immunity in patients with metastatic uveal melanoma when other immunotherapies are incapable.

Identifiants

pubmed: 38627362
doi: 10.1038/s41467-024-46906-4
pii: 10.1038/s41467-024-46906-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2863

Informations de copyright

© 2024. The Author(s).

Références

Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992 pmcid: 3549297 doi: 10.1056/NEJMoa1003466
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797 doi: 10.1056/NEJMoa1910836
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
pubmed: 30643254 pmcid: 6365097 doi: 10.1038/s41588-018-0312-8
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
pubmed: 29262275 pmcid: 6549688 doi: 10.1056/NEJMc1713444
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
pubmed: 34986285 pmcid: 9844513 doi: 10.1056/NEJMoa2109970
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
pubmed: 31570880 doi: 10.1038/s41577-019-0218-4
Algazi, A. P. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122, 3344–3353 (2016).
pubmed: 27533448 doi: 10.1002/cncr.30258
Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J. Clin. Oncol. 39, 586–598 (2021).
pubmed: 33417511 doi: 10.1200/JCO.20.00550
Jager, M. J. et al. Uveal melanoma. Nat. Rev. Dis. Primers 6, 24 (2020).
pubmed: 32273508 doi: 10.1038/s41572-020-0158-0
Singh, A. D., Turell, M. E. & Topham, A. K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118, 1881–1885 (2011).
pubmed: 21704381 doi: 10.1016/j.ophtha.2011.01.040
Niederkorn, J. Y. Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? Front. Immunol. 3, 148 (2012).
pubmed: 22707951 pmcid: 3374415 doi: 10.3389/fimmu.2012.00148
Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28, 2364–2373 (2022).
pubmed: 36229663 pmcid: 9671803 doi: 10.1038/s41591-022-02015-7
Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).
pubmed: 34551229 doi: 10.1056/NEJMoa2103485
Rothermel, L. D. et al. Identification of an immunogenic subset of metastatic uveal melanoma. Clin. Cancer Res. 22, 2237–2249 (2016).
pubmed: 26712692 doi: 10.1158/1078-0432.CCR-15-2294
Chandran, S. S. et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 18, 792–802 (2017).
pubmed: 28395880 pmcid: 5490083 doi: 10.1016/S1470-2045(17)30251-6
Crompton, J. G., Klemen, N. & Kammula, U. S. Metastasectomy for tumor-infiltrating lymphocytes: an emerging operative indication in surgical oncology. Ann. Surg. Oncol. 25, 565–572 (2018).
pubmed: 29188500 doi: 10.1245/s10434-017-6266-8
Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9, 1323–1330 (2017).
pubmed: 29185395 doi: 10.2217/imt-2017-0066
Foroutan, M. et al. Single sample scoring of molecular phenotypes. BMC Bioinform. 19, 404 (2018).
doi: 10.1186/s12859-018-2435-4
Nieto, P. et al. A single-cell tumor immune atlas for precision oncology. Genome Res. 31, 1913–1926 (2021).
pubmed: 34548323 pmcid: 8494216 doi: 10.1101/gr.273300.120
Andreatta, M. & Carmona, S. J. UCell: robust and scalable single-cell gene signature scoring. Comput. Struct. Biotechnol. J. 19, 3796–3798 (2021).
pubmed: 34285779 pmcid: 8271111 doi: 10.1016/j.csbj.2021.06.043
Kang, J. B. et al. Efficient and precise single-cell reference atlas mapping with Symphony. Nat. Commun. 12, 5890 (2021).
pubmed: 34620862 pmcid: 8497570 doi: 10.1038/s41467-021-25957-x
Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu. Rev. Immunol. 27, 591–619 (2009).
pubmed: 19132916 pmcid: 2740335 doi: 10.1146/annurev.immunol.021908.132706
Ivashkiv, L. B. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545–558 (2018).
pubmed: 29921905 pmcid: 6340644 doi: 10.1038/s41577-018-0029-z
Dersh, D., Hollý, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21, 116–128 (2021).
pubmed: 32820267 doi: 10.1038/s41577-020-0390-6
Diamond, M. S. & Farzan, M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13, 46–57 (2013).
pubmed: 23237964 doi: 10.1038/nri3344
Chandran, S. S. et al. Tumor-specific effector CD8+ T cells that can establish immunological memory in humans after adoptive transfer are marked by expression of IL7 receptor and c-myc. Cancer Res. 75, 3216–3226 (2015).
pubmed: 26100671 pmcid: 4537826 doi: 10.1158/0008-5472.CAN-15-0584
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328–1334 (2020).
pubmed: 33303615 pmcid: 8883579 doi: 10.1126/science.abb9847
Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498–1512.e5 (2019).
pubmed: 31097342 pmcid: 6527362 doi: 10.1016/j.immuni.2019.04.010
Chen, J. et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493–497 (2017).
pubmed: 28424516 pmcid: 5565268 doi: 10.1038/nature22076
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
pubmed: 25970248 doi: 10.1038/nature14404
Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623–1642.e20 (2021).
pubmed: 34739845 pmcid: 8861565 doi: 10.1016/j.ccell.2021.10.008
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 25, 3074–3083 (2019).
pubmed: 30635339 pmcid: 6522301 doi: 10.1158/1078-0432.CCR-18-1942
Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997.e24 (2018).
pubmed: 30388455 pmcid: 6410377 doi: 10.1016/j.cell.2018.09.006
Yu, F. et al. Loss of lncRNA-SNHG7 promotes the suppression of hepatic stellate cell activation via miR-378a-3p and DVL2. Mol. Ther. Nucleic Acids 17, 235–244 (2019).
pubmed: 31272073 pmcid: 6610663 doi: 10.1016/j.omtn.2019.05.026
Chen, Y. et al. Knockdown of lncRNA SNHG7 inhibited cell proliferation and migration in bladder cancer through activating Wnt/β-catenin pathway. Pathol. Res. Pract. 215, 302–307 (2019).
pubmed: 30527358 doi: 10.1016/j.prp.2018.11.015
Bian, Z. et al. The role of long noncoding RNA SNHG7 in human cancers (Review). Mol. Clin. Oncol. 13, 45 (2020).
pubmed: 32874575 pmcid: 7453396 doi: 10.3892/mco.2020.2115
Najafi, S. et al. Oncogenic roles of small nucleolar RNA host gene 7 (SNHG7) long noncoding RNA in human cancers and potentials. Front. Cell Dev. Biol. 9, 809345 (2021).
pubmed: 35111760 doi: 10.3389/fcell.2021.809345
Ren, J. et al. Long noncoding RNA SNHG7 promotes the progression and growth of glioblastoma via inhibition of miR-5095. Biochem. Biophys. Res. Commun. 496, 712–718 (2018).
pubmed: 29360452 doi: 10.1016/j.bbrc.2018.01.109
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174 pmcid: 4856474 doi: 10.1016/j.cell.2014.12.033
Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).
pubmed: 26970723 doi: 10.1016/S0140-6736(16)00587-0
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
pubmed: 28650338 pmcid: 5531419 doi: 10.1172/JCI91190
Chiffelle, J. et al. T-cell repertoire analysis and metrics of diversity and clonality. Curr. Opin. Biotechnol. 65, 284–295 (2020).
pubmed: 32889231 doi: 10.1016/j.copbio.2020.07.010
Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220.e15 (2017).
pubmed: 28810145 pmcid: 5619925 doi: 10.1016/j.ccell.2017.07.003
Field, M. G. et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat. Commun. 9, 116 (2018).
pubmed: 29317634 pmcid: 5760704 doi: 10.1038/s41467-017-02428-w
Carvajal, R. D. et al. Advances in the clinical management of uveal melanoma. Nat. Rev. Clin. Oncol. 20, 99–115 (2023).
pubmed: 36600005 doi: 10.1038/s41571-022-00714-1
Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J. Clin. Oncol. 39, 599–607 (2021).
pubmed: 33125309 doi: 10.1200/JCO.20.00605
Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 (2020).
pubmed: 32313009 pmcid: 7171146 doi: 10.1038/s41467-020-15606-0
Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. Nat. Genet. 51, 1123–1130 (2019).
pubmed: 31253977 pmcid: 6632071 doi: 10.1038/s41588-019-0440-9
Durante, M. A. et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 11, 496 (2020).
pubmed: 31980621 pmcid: 6981133 doi: 10.1038/s41467-019-14256-1
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723.e14 (2017).
pubmed: 28486109 pmcid: 5650691 doi: 10.1016/j.ccell.2017.04.003
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
pubmed: 28187290 pmcid: 5391692 doi: 10.1016/j.cell.2017.01.017
Wang, Y. et al. Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. Nat. Genet. 55, 19–25 (2023).
pubmed: 36624340 pmcid: 10155259 doi: 10.1038/s41588-022-01268-9
Bugter, J. M., Fenderico, N. & Maurice, M. M. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat. Rev. Cancer 21, 5–21 (2021).
pubmed: 33097916 doi: 10.1038/s41568-020-00307-z
Mariani, P. et al. Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases. Br. J. Cancer 129, 772–781 (2023).
pubmed: 37443346 doi: 10.1038/s41416-023-02331-w
Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).
pubmed: 34215730 pmcid: 8253860 doi: 10.1038/s41467-021-24343-x
Yusko, E. et al. Association of tumor microenvironment T-cell repertoire and mutational load with clinical outcome after sequential checkpoint blockade in melanoma. Cancer Immunol. Res. 7, 458–465 (2019).
pubmed: 30635271 pmcid: 6397694 doi: 10.1158/2326-6066.CIR-18-0226
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949.e16 (2017).
pubmed: 29033130 pmcid: 5685550 doi: 10.1016/j.cell.2017.09.028
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505 pmcid: 4246418 doi: 10.1038/nature13954
Hanada, K. I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479–493.e6 (2022).
pubmed: 35452604 pmcid: 9196205 doi: 10.1016/j.ccell.2022.03.012
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
pubmed: 35113651 pmcid: 8996692 doi: 10.1126/science.abl5447
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774 doi: 10.1016/j.ejca.2008.10.026
Kendig, K. I. et al. Sentieon DNASeq variant calling workflow demonstrates strong computational performance and accuracy. Front. Genet. 10, 736 (2019).
pubmed: 31481971 pmcid: 6710408 doi: 10.3389/fgene.2019.00736
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform. 43, 11.10.11–11.10.33 (2013).
Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).
pubmed: 27100738 pmcid: 4839673 doi: 10.1371/journal.pcbi.1004873
Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 21, 974–984 (2011).
pubmed: 21324876 pmcid: 3106330 doi: 10.1101/gr.114876.110
Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).
pubmed: 26647377 doi: 10.1093/bioinformatics/btv710
Jeffares, D. C. et al. Transient structural variations have strong effects on quantitative traits and reproductive isolation in fission yeast. Nat. Commun. 8, 14061 (2017).
pubmed: 28117401 pmcid: 5286201 doi: 10.1038/ncomms14061
Geoffroy, V. et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics 34, 3572–3574 (2018).
pubmed: 29669011 doi: 10.1093/bioinformatics/bty304
Kandoth, C. mskcc/vcf2maf: vcf2maf v1.6.19 (2020).
McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4
Smigielski, E. M., Sirotkin, K., Ward, M. & Sherry, S. T. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 28, 352–355 (2000).
pubmed: 10592272 pmcid: 102496 doi: 10.1093/nar/28.1.352
Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878 doi: 10.1093/nar/gky1015
Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747–1756 (2018).
pubmed: 30341162 pmcid: 6211645 doi: 10.1101/gr.239244.118
Paniccia, A. et al. Prospective, multi-institutional, real-time next-generation sequencing of pancreatic cyst fluid reveals diverse genomic alterations that improve the clinical management of pancreatic cysts. Gastroenterology 164, 117–133.e17 (2023).
pubmed: 36209796 doi: 10.1053/j.gastro.2022.09.028
Andrews, S. FastQC: a quality control tool for high throughput sequence data (2010).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
Kopylova, E., Noé, L. & Touzet, H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics 28, 3211–3217 (2012).
pubmed: 23071270 doi: 10.1093/bioinformatics/bts611
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Frankish, A. et al. GENCODE 2021. Nucleic Acids Res. 49, D916–D923 (2021).
pubmed: 33270111 doi: 10.1093/nar/gkaa1087
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700 doi: 10.1093/bioinformatics/btu638
Cunningham, F. et al. Ensembl 2022. Nucleic Acids Res. 50, D988–D995 (2022).
pubmed: 34791404 doi: 10.1093/nar/gkab1049
Smedley, D. et al. The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Res. 43, W589–598 (2015).
pubmed: 25897122 pmcid: 4489294 doi: 10.1093/nar/gkv350
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Blighe, K. PCAtools: PCAtools: Everything Principal Components Analysis. R package version 2.10.0 (2022).
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
doi: 10.1186/1471-2105-14-7
Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216–221 (2022).
pubmed: 35325185 pmcid: 9252805 doi: 10.1093/nar/gkac194
Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778 pmcid: 8454663
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 47, D330–D338 (2019).
Orenbuch, R. et al. arcasHLA: high-resolution HLA typing from RNAseq. Bioinformatics 36, 33–40 (2020).
pubmed: 31173059 doi: 10.1093/bioinformatics/btz474
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071 doi: 10.1038/nmeth.3364
Nazarov, V. et al. immunarch: Bioinformatics Analysis of T-Cell and B-Cell Immune Repertoires R package version 1.0.0 (2022).
Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601 pmcid: 5241818 doi: 10.1038/ncomms14049
Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, 12 (2020)
Choudhary, S. & Satija, R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 23, 27 (2022).
pubmed: 35042561 pmcid: 8764781 doi: 10.1186/s13059-021-02584-9
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329–337.e4 (2019).
pubmed: 30954475 pmcid: 6853612 doi: 10.1016/j.cels.2019.03.003
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Phipson, B. et al. propeller: testing for differences in cell type proportions in single cell data. Bioinformatics 38, 4720–4726 (2022).
pubmed: 36005887 pmcid: 9563678 doi: 10.1093/bioinformatics/btac582
Borcherding, N., Bormann, N. L. & Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res 9, 47 (2020).
pubmed: 32789006 pmcid: 7400693 doi: 10.12688/f1000research.22139.1
The R Development Core Team. R: A Language and Environment for Statistical Computing (2021).
RStudio Team. RStudio: Integrated Development for R (2020).
Kassambara, A. et al. survminer: Drawing Survival Curves using ‘ggplot2’. R package version 0.4.9 (2021).
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
pubmed: 27207943 doi: 10.1093/bioinformatics/btw313
Wickham, H. et al. Welcome to the tidyverse. J. Open Source Softw. 4, 1686 (2019).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, 2016).
Brewer, C. RColorBrewer: ColorBrewer Palettes. R package version 1.1-3 (2022).
Dawson, C. ggprism: A. ‘ggplot2’ Extension Inspired by ‘GraphPad Prism’. R package version 1.0.4 (2022).
Pedersen, T. patchwork: The Composer of Plots. R package version 1.1.2 (2022).
Bedward, M., Eppstein, D. & Menzel, P. packcircles: Circle Packing. R package version 0.3.5 (2022).

Auteurs

Shravan Leonard-Murali (S)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.

Chetana Bhaskarla (C)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Ghanshyam S Yadav (GS)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Sudeep K Maurya (SK)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Chenna R Galiveti (CR)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Joshua A Tobin (JA)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Rachel J Kann (RJ)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Eishan Ashwat (E)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Patrick S Murphy (PS)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Anish B Chakka (AB)

Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.

Vishal Soman (V)

Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.

Paul G Cantalupo (PG)

Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.

Xinming Zhuo (X)

UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.

Gopi Vyas (G)

UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.

Dara L Kozak (DL)

UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.

Lindsey M Kelly (LM)

UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.

Ed Smith (E)

UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.

Uma R Chandran (UR)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.

Yen-Michael S Hsu (YS)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
UPMC Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, PA, USA.
Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Udai S Kammula (US)

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. kammulaus@upmc.edu.
Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. kammulaus@upmc.edu.
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. kammulaus@upmc.edu.

Classifications MeSH